S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis

World Journal of Gastroenterology

Volumn 20, Issue 1, 2014, Pages 310-318

  Liu, Guo Fang ^a   Tang, Dong ^a   Li, Ping ^a   Wang, Su ^a   Xu, Ya Xiang ^a   Long, Ai Hua ^a   Zhou, Nian Lan ^a   Zhang, Li Li ^a   Chen, Jie ^a   Xiang, Xiao Xing ^a  

^a NORTHERN JIANGSU PEOPLE S HOSPITAL   (China)

Author keywords

Advanced gastric cancer; Chemotherapy; Meta analy sis; Overall survival; S 1

Indexed keywords

BIOLOGICAL MARKER; CISPLATIN; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; IRINOTECAN; PACLITAXEL; TRASTUZUMAB;

ANEMIA; ANOREXIA; ARTICLE; CANCER RADIOTHERAPY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; ESOPHAGEAL ADENOCARCINOMA; FATIGUE; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; META ANALYSIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY TUMOR; PROGRESSION FREE SURVIVAL; SENSITIVITY ANALYSIS; STOMACH CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ADVANCED GASTRIC CANCER; CHEMOTHERAPY; META-ANALYSIS; OVERALL SURVIVAL; S-1;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG COMBINATIONS; HUMANS; ODDS RATIO; OXONIC ACID; RISK FACTORS; STOMACH NEOPLASMS; TEGAFUR; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891757313     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i1.310     Document Type: Article

References (26)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108 [PMID: 15761078 DOI: 10.3322/canjclin.55.2.74]
2. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin 2000; 50: 7-33 [PMID: 10735013 DOI: 10.3322/canjclin.50.1.7]
3. Ajani JA. Chemotherapy for gastric carcinoma: new and old options. Oncology (Williston Park) 1998; 12: 44-47 [PMID: 9830625]
4. Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K, Fukushima M. Development of a novel form of an oral 5-fuorouracil derivative (S-1) directed to the poten-tiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 1996; 7: 548-557 [PMID: 8862723 DOI: 10.1097/00001813-199607000-00010]
5. Maehara Y. S-1 in gastric cancer: a comprehensive review. Gastric Cancer 2003; 6 Suppl 1: 2-8 [PMID: 12775012 DOI: 10.1007/s10120-003-0232-9]
6. Koizumi W, Tanabe S, Saigenji K, Ohtsu A, Boku N, Na-gashima F, Shirao K, Matsumura Y, Gotoh M. Phase I/II study of S-1 combined with cisplatin in patients with advanced gastric cancer. Br J Cancer 2003; 89: 2207-2212 [PMID: 14676796 DOI: 10.1038/sj.bjc.6601413]
7. Yoshida K, Ninomiya M, Takakura N, Hirabayashi N, Taki-yama W, Sato Y, Todo S, Terashima M, Gotoh M, Sakamoto J, Nishiyama M. Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3402-3407 [PMID: 16740764 DOI: 10.1158/1078-0432.CCR-05-2425]
8. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, Tsukuma H, Tsujinaka T, Furukawa H, Ta-guchi T. Phase II study of a combination of S-1 and pacli-taxel in patients with unresectable or metastatic gastric cancer. Oncology 2008; 74: 37-41 [PMID: 18544958 DOI:10.1159/000138978]
9. Uedo N, Narahara H, Ishihara R, Takiuchi H, Goto M, Fujitani K, Hirao M, Tsujinaka T, Imano M, Furukawa H, Tsukuma H, Taguchi T. Phase II study of a combination of irinotecan and S-1 in patients with advanced gastric cancer (OGSG0002). Oncology 2007; 73: 65-71 [PMID: 18334851 DOI: 10.1159/000120630]
10. Group CEPaOoC. EPOC resources for review authors, 2011. Available from: URL: http://epoc.cochrane.org/epoc-resources
11. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216 [PMID: 10655437 DOI: 10.1093/jnci/92.3.205]
12. Sutton AJ, Abrams KR, Jones DR, Sheldon TA, Song F. Methods for meta-analysis in medical research. Chichester: Wiley, 2000: 49-53
13. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999; 18: 321-359 [PMID: 10070677 DOI: 10.1002/(SICI)1097-0258]
14. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315: 629-634 [PMID: 9310563 DOI: 10.1136/bmj.315.7109.629]
15. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994; 50: 1088-1101 [PMID: 7786990 DOI: 10.2307/2533446]
16. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Tak-agi M, Miyashita K, Nishizaki T, Kobayashi O, Takiyama W, Toh Y, Nagaie T, Takagi S, Yamamura Y, Yanaoka K, Orita H, Takeuchi M. S-1 plus cisplatin versus S-1 alone for frst-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008; 9: 215-221 [PMID: 18282805 DOI: 10.1016/S1470-2045(08)70035-4]
17. Komatsu Y, Takahashi Y, Kimura Y, Oda H, Tajima Y, Tamu-ra S, Sakurai J, Wakasugi T, Tatebe S, Takahashi M, Sakata Y, Kitajima M, Sakamoto J, Saji S. Randomized phase II trial of frst-line treatment with tailored irinotecan and S-1 therapy versus S-1 monotherapy for advanced or recurrent gastric carcinoma (JFMC31-0301). Anticancer Drugs 2011; 22: 576-583 [PMID: 21512394 DOI: 10.1097/CAD.0b013e328245b509]
18. Narahara H, Iishi H, Imamura H, Tsuburaya A, Chin K, Imamoto H, Esaki T, Furukawa H, Hamada C, Sakata Y. Randomized phase III study comparing the efficacy and safety of irinotecan plus S-1 with S-1 alone as frst-line treatment for advanced gastric cancer (study GC0301/TOP-002). Gastric Cancer 2011; 14: 72-80 [PMID: 21340666 DOI: 10.1007/ s10120-011-0009-5]
19. Wang X, Wang ML, Zhou LY, Lu XY, Yang JF, Yu HG. Randomized phase II study comparing paclitaxel with S-1 vs. S-1 as frst-line treatment in patients with advanced gastric cancer. Clin Transl Oncol 2013; 15: 836-842 [PMID: 23381898 DOI: 10.1007/s12094-013-1012-6]
20. Kubota T. The role of S-1 in the treatment of gastric cancer. Br J Cancer 2008; 98: 1301-1304 [PMID: 18362933 DOI: 10.1038/sj.bjc.6604332]
21. Huang J, Cao Y, Wu L, Liao C, He Y, Gao F. S-1-based therapy versus 5-FU-based therapy in advanced gastric cancer: a meta-analysis. Med Oncol 2011; 28: 1004-1011 [PMID: 20552300 DOI: 10.1007/s12032-010-9594-0]
22. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Myeloid growth factors-Version v1, 2011. Available from: URL: http://www.nccn.org
23. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Cancer-and chemotherapy-induced anemia-Version v2, 2012. Available from: URL, http://www.nccn.org.
24. Ippoliti C. Antidiarrheal agents for the management of treatment-related diarrhea in cancer patients. Am J Health Syst Pharm 1998; 55: 1573-1580 [PMID: 9706182]
25. Thuss-Patience PC, Kretzschmar A, Bichev D, Deist T, Hinke A, Breithaupt K, Dogan Y, Gebauer B, Schumacher G, Reichardt P. Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer--a randomised phase III study of the Arbeitsgemein-schaft Internistische Onkologie (AIO). Eur J Cancer 2011; 47:2306-2314 [PMID: 21742485 DOI: 10.1016/j.ejca.2011.06.002]
26. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK. Trastuzum-ab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010; 376: 687-697 [PMID: 20728210 DOI: 10.1016/S0140-6736(10)61121-x]